Orchestra BioMed™ Announces Global Strategic Partnership with Terumo Corporation for Development and Commercialization of Virtue® Sirolimus-Eluting Balloon
June 13, 2019 07:00 ET
|
Orchestra BioMed
Virtue® SEB is expected to become a flagship therapeutic product for Terumo and will strengthen its broad US and global portfolio of interventional solutionsTerms of the partnership include...
Orchestra BioMed™ Presents Clinical Data at EuroPCR 2019 Demonstrating Safety and Efficacy of BackBeat Cardiac Neuromodulation Therapy (CNT)
May 23, 2019 07:30 ET
|
Orchestra BioMed
Novel implantable bioelectronic treatment delivers immediate, substantial, and sustained reduction in blood pressureData showed 14.2 mmHg reduction in 24-hour ambulatory systolic blood pressure at...
Orchestra BioMed™ Receives FDA Breakthrough Device Designation for Virtue® Sirolimus-Eluting Balloon (SEB)
April 24, 2019 09:00 ET
|
Orchestra BioMed
First and only non-coated sirolimus-eluting angioplasty balloon system to show promising clinical resultsPotential to offer significant advantages for treatment of coronary in-stent restenosis (ISR),...